The European Commission (EC) has approved Otsuka Pharmaceutical and Astex Pharmaceuticals’ Inaqovi (oral decitabine and cedazuridine) as monotherapy for the tre 19 September 2023
The US Food and Drug Administration (FDA) has accepted a supplemental biologics license application (sBLA) for Altuviiio [antihemophilic factor (recombinant), F 13 September 2023
US biotech Star Therapeutics has announced the closing of an oversubscribed $90 million Series C financing to continue growing its antibody therapies and portfo 5 September 2023
Following its first Chinese approval earlier this year, a next generation BTK blocker, Calquence (acalabrutinib), has picked up another nod in the country. 4 September 2023
Bristol Myers Squibb has picked up a nod in the USA for its anemia med Reblozyl (luspatercept-aamt), a first-in-class therapy which promotes late-stage red bloo 30 August 2023
While Geron had hoped for a Priority Review for its rare blood cancer candidate imetelstat, the US regulator has confirmed a regular review will now take place, 23 August 2023
Gilead Sciences has been hit with a partial clinical hold by the US Food and Drug Administration (FDA) on the initiation of new patients in US studies evaluatin 21 August 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.